US › Healthcare

Dyadic International Inc (DYAI)

US · Healthcare · Biotechnology

$1.08+1.89%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.1M
Revenue YoY
+506.7%
Net profit
$-2.0M
Profit YoY
+3.6%
EPS
$-0.05
EPS estimate
$-0.04
Net margin
-175.9%

EPS came in at -0.05 against a street estimate of -0.04 — a miss of 25.0%.

Key statistics

Market cap
$38.3M
Forward P/E
15.8
P/B
21.01
Book value
$-0.01
EPS (TTM)
$-0.21
52-week high
$1.60
52-week low
$0.65
50-day MA
$0.92
200-day MA
$0.90
Beta
1.15

Analyst view

Analysts rate Dyadic International Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $6.00.

Shareholding

Insiders
25.27%
Institutions
15.06%

Largest institutional holders

FundStake
Apis Capital Advisors, LLC3.49%
Vanguard Capital Management, LLC2.55%
Chapin Davis Inc2.44%
BB&T Corp.0.90%
Geode Capital Management, LLC0.86%
BlackRock Inc0.76%
Vanguard Fiduciary Trust Co0.38%
Marathon Capital Management LLC0.30%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Dyadic International Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.